Literature DB >> 667799

Meningeal carcinomatosis in breast cancer.

H Y Yap, B S Yap, C K Tashima, A DiStefano, G R Blumenschein.   

Abstract

Twenty-five breast cancer patients with meningeal carcinomatosis seen over a period of 16 months were reviewed. In all cases, the clinical diagnosis was made in the presence of diverse neurological manifestations by the demonstration of malignant cells in the cerebrospinal fluid. In ten patients, the clinical diagnosis was documented at autopsy. All patients were receiving systemic chemotherapy at the time the diagnosis of meningeal carcinomatosis was made. In 9 of the 25 patients, meningeal involvement was associated with progression of systemic metastases, while 5 exhibited stable or partial remission from systemic metastases and 7 were in complete remission at the time of their CNS relapse. CNS involvement was the first manifestation of recurrent disease from breast cancer in 4 of 25 patients. Meningeal involvement can, therefore, occur at any time during the course of breast cancer. With increasing diagnostic awareness and the employment of several therapeutic strategies, the prognosis of these patients, though poor, was significantly improved over that of historical control patients.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 667799     DOI: 10.1002/1097-0142(197807)42:1<283::aid-cncr2820420142>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  46 in total

Review 1.  Meningeal metastases: clinical aspects and diagnosis.

Authors:  F Formaglio; A Caraceni
Journal:  Ital J Neurol Sci       Date:  1998-06

2.  Early diagnosis and treatment of spinal epidural metastasis in breast cancer: a prospective study.

Authors:  W Boogerd; J J van der Sande; R Kröger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154

3.  Meningeal carcinomatosis.

Authors:  W R Shapiro
Journal:  West J Med       Date:  1991-03

4.  Classification of Leptomeningeal Metastases from Solid Organ Malignancies and Clinical Outcomes: Series from a Cancer Research Centre.

Authors:  Sundriyal Deepak; Arya Lima; Saha Rajat; Walia Meenu
Journal:  Indian J Surg Oncol       Date:  2020-04-17

5.  Carcinomatous meningitis: antibody-guided therapy with I-131 HMFG1.

Authors:  R P Moseley; J C Benjamin; R D Ashpole; N M Sullivan; J A Bullimore; H B Coakham; J T Kemshead
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-03       Impact factor: 10.154

6.  Durable clinical benefit with exemestane in leptomeningeal metastasis of breast cancer.

Authors:  Luis Miguel Navarro Martín; Alberto Ocaña Fernández; Cesar Augusto Rodríguez Sánchez; Isabel Ruiz Martín; Juan Jesús Cruz Hernández
Journal:  Clin Transl Oncol       Date:  2005-09       Impact factor: 3.405

7.  Leptomeningeal metastasis from ovarian carcinoma successfully treated by the intraventricular administration of methotrexate.

Authors:  Yasushi Goto; Noriyuki Katsumata; Shunichi Nakai; Yuko Sasajima; Kan Yonemori; Tsutomu Kouno; Chikako Shimizu; Masashi Ando; Yasuhiro Fujiwara
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

Review 8.  Patterns of metastasis and natural courses of breast carcinoma.

Authors:  Y T Lee
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

9.  Response of neoplastic meningitis from solid tumors to oral capecitabine.

Authors:  Pierre Giglio; Ivo W Tremont-Lukats; Morris D Groves
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

10.  An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis.

Authors:  Kurt A Jaeckle; Tracy Batchelor; Steven J O'Day; Surasak Phuphanich; Pamela New; Glenn Lesser; Allen Cohn; Mark Gilbert; Robert Aiken; Deborah Heros; Lisa Rogers; Eric Wong; Dorcas Fulton; John C Gutheil; Said Baidas; Julia M Kennedy; Warren Mason; Paul Moots; Christy Russell; Lode J Swinnen; Stephen B Howell
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.